Medical Director, Washington Cancer Institute
MedStar Washington Hospital Center
Professor of Medicine, Georgetown University
Minority cancer patients account for less than 2% of clinical trial study populations. There are multiple reasons for their underrepresentation, including lack of education on clinical trials, cultural beliefs and attitudes, and clinical trial study designs that exclude many minority patients because of other illness or existing conditions, which tend to be more common in minority and underserved populations. Dr. Sandra Swain is working to address some of the barriers to clinical trial participation in a group of African American breast cancer patients who are experiencing other illness that could impact their breast cancer outcomes. Her study will draw from patient interviews and focus group discussions to develop a protocol for an exercise intervention study that caters to this unique group of patients. Since randomized clinical trials on ethnic minorities, especially African-American women is lacking, this study will provide valuable insight in addressing the disparities in breast cancer outcomes.
Sandra M. Swain, MD, FACP is the Medical Director of the Washington Cancer Institute, MedStar Washington Hospital Center, in Washington, DC. She is a Professor of Medicine at Georgetown University and Adjunct Professor of Medicine at F. Edward Hebert School of Medicine. She was previously the Deputy Branch Chief of the Medicine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health and was a tenured Principal Investigator and Chief of the Breast Cancer Section and of the Cancer Therapeutics Branch. She obtained an undergraduate degree in Chemistry from the University of North Carolina in 1975, and a MD from the University of Florida in Gainesville in 1980. She completed her residency in internal medicine at Vanderbilt University in 1983 followed by a fellowship in Medical Oncology at the National Cancer Institute in 1986.
Dr. Swain’s research interests include clinical trials and translational research in metastatic and inflammatory breast cancer, adjuvant therapy for breast cancer, cardiotoxicity, and health care disparities. Her research has been funded by the National Institutes of Health, Susan G. Komen Foundation, Breast Cancer Research Foundation, and the Avon Foundation. She has published over 230 articles and is recognized as a leading international figure in breast cancer. She received the Susan G. Komen for the Cure Community Global Award of Distinction in 2012. Dr. Swain was president of the American Society of Clinical Oncology (ASCO) in 2012-13, served as a member of the ASCO Board and is a member of the Conquer Cancer Foundation Board.